Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

How Much Risk Should Big Pharma Accept To Close Deals In China? (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

[Part 1 of this feature appeared Jan. 17 in PharmAsia News. Part 2 continues with the examination of China deals with Sanofi-Aventis' VP-Business Development Arjun Oberoi and Simcere President Yehong Zhang, who presented during the 29th annual J.P. Morgan Healthcare conference in San Francisco last week.]

You may also be interested in...



WuXi Forms JV With PRA To Expand Clinical Services In China

WuXi PharmaTech forms a joint venture with U.S. contract research organization PRA to grow its clinical capabilities in China; the move expands PRA’s reach to 16 Chinese cities.

PharmAsia News Favorite Stories From 2011

If you missed some of the highlights of 2011, here’s your opportunity to check out some of our favorite stories from the year, as chosen by the editors of PharmAsia News.

From Biologics To Corporate Venture, China's Leading CRO Continues To Evolve

In an effort to boost its biological capabilities and continue its march into additional integrated services, China's leading contract research organization WuXi PharmaTech has acquired Abgent Inc., a provider of biological research agent products and services

Related Content

UsernamePublicRestriction

Register

SC031354

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel